Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
6.66% $12.01
America/New_York / 27 nov 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 48.63 mill |
EPS: | -74.15 |
P/E: | -0.162 |
Earnings Date: | Mar 04, 2024 |
SharesOutstanding: | 4.05 mill |
Avg Daily Volume: | 0.0595 mill |
RATING 2023-12-26 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.162 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.162 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 16.91 - 21.69 ( +/- 12.36%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Fairmount Funds Management Llc | Buy | 406 038 | Common Stock |
2023-12-29 | Fairmount Funds Management Llc | Sell | 3 435 480 | Common Stock |
2023-12-22 | Burrows Scott L | Buy | 134 953 | Common Stock |
2023-12-07 | Fairmount Funds Management Llc | Buy | 16 667 | Series B Preferred Stock |
2023-11-22 | Albers Jeffrey W. | Buy | 50 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-5.37 |
Last 85 transactions |
Buy: 64 136 392 | Sell: 71 129 759 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $12.01 (6.66% ) |
Volume | 0.0432 mill |
Avg. Vol. | 0.0595 mill |
% of Avg. Vol | 72.62 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.